Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients; 80% ORR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback